89bio Inc (ETNB)
7.90
+0.12
(+1.54%)
USD |
NASDAQ |
May 31, 16:00
7.90
0.00 (0.00%)
Pre-Market: 20:00
89bio Cash from Financing (Quarterly): 21.03M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 21.03M |
December 31, 2023 | 162.17M |
September 30, 2023 | -1.48M |
June 30, 2023 | 30.77M |
March 31, 2023 | 321.65M |
December 31, 2022 | 21.01M |
September 30, 2022 | 68.63M |
June 30, 2022 | 28.16M |
March 31, 2022 | 0.029M |
December 31, 2021 | 21.89M |
September 30, 2021 | 0.072M |
Date | Value |
---|---|
June 30, 2021 | 1.692M |
March 31, 2021 | 0.216M |
December 31, 2020 | -0.312M |
September 30, 2020 | 158.29M |
June 30, 2020 | -0.065M |
March 31, 2020 | 0.009M |
December 31, 2019 | 88.38M |
September 30, 2019 | 0.488M |
June 30, 2019 | 18.84M |
March 31, 2019 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.48M
Minimum
Sep 2023
321.65M
Maximum
Mar 2023
47.07M
Average
19.92M
Median
Cash from Financing (Quarterly) Benchmarks
Akero Therapeutics Inc | 366.94M |
Madrigal Pharmaceuticals Inc | 573.71M |
Viking Therapeutics Inc | 606.04M |
Galectin Therapeutics Inc | 10.00M |
Terns Pharmaceuticals Inc | 0.00 |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -39.72M |
Cash from Investing (Quarterly) | -79.90M |
Free Cash Flow | -138.82M |
Free Cash Flow Per Share (Quarterly) | -0.4144 |
Free Cash Flow Yield | -21.49% |